Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family

Luo, Cong; Zhu, Yaping; Jiang, Tie-jun; Lu, Xiaoyong; Zhang, Wo; Jing, Qifeng; Li, Jia; Pang, Linrong; Chen, Kangjie; Qiu, Fuming; Yu, Xijie; Yang, Jiahui; Huang, Jian

doi:10.1016/j.tox.2006.10.020

Cited by 69 publications

(68 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study used matrine to treat human gastric cancer cells (MKN45). In that study, matrine activated the caspase-3 and -7 pathways and increased the pro-apoptotic molecules of the Bcl-2 family (Bok, Bak, Bax, Puma, and Bim) to inhibit cell proliferation and induce apoptosis in a dosedependent manner [15] . The treatment of human gallbladder carcinoma cells (GBC-SD) with matrine was associated with an inhibition of cancer cell growth, induction of G 1 cell cycle arrest and activation of apoptosis in a dose-and time-dependent manner.…”

Section: Introductionmentioning

confidence: 90%

Anti-tumor activities of active ingredients in Compound Kushen Injection

Wang¹,

et al. 2015

View full text Add to dashboard Cite

Kushen (Radix Sophorae Flavescentis) has a long history of use for the treatment of tumors, inflammation and other diseases in traditional Chinese medicine. Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from Kushen and Baituling (Rhizoma Smilacis Glabrae). The main principles of CKI are matrine (MT) and oxymatrine (OMT) that exhibit a variety of pharmacological activities, including anti-inflammatory, anti-allergic, anti-viral, anti-fibrotic and cardiovascular protective effects. Recent evidence shows that these compounds also produce anti-cancer actions, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy-and/or radiotherapy-induced toxicity when combined with chemotherapeutic drugs. In this review, we summarize recent progress in studying the anti-cancer activities of MT, OMT and CKI and their potential molecular targets, which provide clues and references for further study.

show abstract

Section: Introductionmentioning

confidence: 90%

Anti-tumor activities of active ingredients in Compound Kushen Injection

Wang¹,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Matrine also inhibited the invasiveness and matastasis of human malignant melanoma cell line A375 . Some studies reported that matrine induced gastric cancer MKN45 cell apoptosis (Luo et al 2007) and reduced Hela cell adhesion and migration ). However, the effects of matrine on human NSCLC and hepatoma as well as the mechanisms of action are largely unknown.…”

Section: Introductionmentioning

confidence: 99%

Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration

Zhang

et al. 2009

Cytotechnology

View full text Add to dashboard Cite

The purpose of this study is to investigate in vitro and ex vivo effects of matrine on the growth of human lung cancer and hepatoma cells and the cancer cell migration as well as the expressions of related proteins in the cancer cells. Matrine significantly inhibited the in vitro and ex vivo growth of human non-small cell lung cancer A549 and hepatoma SMMC-7721 cells. Matrine induced the apoptosis in A549 and SMMC-7721 cells. Western blot analysis indicated that matrine dose-dependently down-regulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein bax, eventually leading the reduction of ratios of Bcl-2/Bax proteins in A549 and SMMC-7721 cells. Furthermore, matrine significantly suppressed the A549 cell migration without reducing the cell viability. In addition, matrine dramatically reduced the secretion of vascular endothelial growth factor A in A549 cells. More importantly, matrine markedly enhanced the anticancer activity of anticancer agent trichostatin A (the histone deacetylase inhibitor) by strongly reducing the viability and/or the ratio of Bcl-2/Bax protein in A549 cells. Our findings suggest that matrine may have the broad therapeutic and/or adjuvant therapeutic application in the treatment of human non-small cell lung cancer and hepatoma.

show abstract

“…Matrine has been extensively used in China for the treatment of viral hepatitis and cardiac diseases (Liu et al, 2007). Matrine also exhibits inhibition activity toward many tumour cells (such as HeLa cell and gastric cancer MKN45 cell) (Galasso et al, 2006;Luo et al, 2007;Ruan et al, 2006;Zhang et al, 2001Zhang et al, & 2007. In some case, they exhibit significant enhanced antitumour activity, such as 21 to SW480, 22 to HeLa, HepG2 and MCF-7, which exceed matrine and cisplatin, and display synergistic contribution of their components.…”

Section: Matrine-metal Based Anticancer Agentsmentioning

confidence: 99%